Company
Heron Therapeutics
Heron Therapeutics has 12 drugs tracked on RxWires: 6 post-market, 1 in Phase 3, 4 in Phase 2, 1 in Phase 1/2.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Aprepitant Injection | Post-Market | PONV |
| MMA regimen | Post-Market | Postoperative Pain |
| Bupivacaine Hydrochloride | Post-Market | Analgesia |
| Bupivacaine liposome injectable suspension | Post-Market | Analgesia |
| HTX-011 | Post-Market | Postoperative Pain |
| ZYNRELEF 200Mg-6Mg Extended-Release Solution | Post-Market | Post Operative Pain, Acute |
| APF530 | Phase 3 | Chemotherapy-induced Nausea and Vomiting |
| GRANISETRON EXTENDED RELEASE INJECTION (GERSC) | Phase 2 | Chemotherapy-induced Nausea and Vomiting |
| HTX-011A | Phase 2 | Postoperative Pain |
| Bupivacaine HCI without epinephrine | Phase 2 | Post-Operative Pain |
| HTX-011B | Phase 2 | Postoperative Pain |
| HTX-034 low dose | Phase 1/2 | Bunions |
Latest
No recent events.
Follow Heron Therapeutics on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.